Closing
Do GLP-1 receptor agonists improve inflammation & biomarkers versus placebo?
Mostly studied in obesity & overweight. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, the results disagree.
NoUnsureYes
- Belief
- 0.50 (range 0.00–0.55)
- Trials for
- 2
- Trials against
- 1
- Inconclusive
- 3
Already under way
- SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate…NCT07462663 · not yet recruiting · started 2027
- A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and ObesityNCT07731256 · not yet recruiting · started 2027
- GLIDE-HF Registry: A Prospective, Single-Center, Observational Cohort of Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction, With…NCT07787936 · not yet recruiting · started 2027
- Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled…NCT07179120 · not yet recruiting · started 2026
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder - OBOE-MayoNCT07213466 · recruiting · started 2026
The evidence so far
- Registered trials
- 249
- With posted results
- 54
- Published papers
- 3
Of 20 decided analyses: 2 favor glp-1 receptor agonists, 17 find no difference, 1 favor the comparator.
Papers
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.Meta-analysis / systematic review · 2017
- Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.Meta-analysis / systematic review · 2021
- The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.Trial report · 2020
Trials
- Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney DiseaseNCT04865770 · 7 posted results
- Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up PeriodNCT00781937 · 1 posted result
- Effects of the Glucagon Like-peptide 1 (GLP-1) Receptor Agonist Liraglutide on Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: a Randomized Controlled TrialNCT04881110 · 1 posted result
- Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated LipohypertrophyNCT04019197 · 9 posted results
- The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride ArmNCT00620282 · 3 posted results
- A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)NCT03480022 · 1 posted result
- Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility StudyNCT06072963
- Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes MellitusNCT01761318